Alteogen: Block Deal Sale of About 3% of Shares
On 27 March, Alteogen announced that Jeong Hye-shin, former Alteogen Chief Strategy Officer (CSO), sold 1.6 million shares of Alteogen stock (3% of...
540 Views
Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
Alteogen modifies license agreement with Merck, granting exclusive global rights for ALT-B4 for pembrolizumab for an upfront payment of $20M and...
532 Views
Alteogen (196170 KS): First Proprietary Product Approval in Korea To Improve Revenue Visibility
Alteogen’s first proprietary recombinant human hyaluronidase liquid product, Tergase (ALT-BB4) is undergoing approval process in Korea and is...
588 Views
KRX Foreign Holding Weekly (Jun 28th): Samsung Electronics, Sk Hynix, Samsung SDI, Celltrion
We analyzed KRX foreign holding data for the past week and highlighted foreign holding changes in Samsung Electronics, Sk Hynix, Samsung SDI,...
223 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
586 Views